熱門資訊> 正文
Pyxis Oncology GAAP每股收益为-0.29美元
2024-08-15 19:26
- Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.29.
- The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide cash runway into the second half of 2026 and enable the Company to fund the next phase of PYX-201 clinical development, which the Company plans to announce in the fall of 2024.
More on Pyxis Oncology
- Pyxis Oncology: Promising Research Amid Cash Constraints
- Pyxis Oncology draws Buy at Stifel on lead asset
- Seeking Alpha’s Quant Rating on Pyxis Oncology
- Historical earnings data for Pyxis Oncology
- Financial information for Pyxis Oncology
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
